Aethlon medical announces financial results for the fiscal fourth quarter ended march 31, 2025, and provides corporate update

Three patients treated in hemopurifier® cancer trial; indian regulatory approval achieved; operating expenses reduced; r&d advances support expanded indications including long covid conference call to be held today at 4:30 p.m. et san diego , june 26, 2025 /prnewswire/ -- aethlon medical, inc. (the company or aethlon) (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended march 31, 2025, and provided an update on recent developments.
AEMD Ratings Summary
AEMD Quant Ranking